Somatostatin receptor 2–targeting compounds
DAS Duijzentkunst, DJ Kwekkeboom… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled
somatostatin analogs represent a milestone in the development of theranostic compounds …
somatostatin analogs represent a milestone in the development of theranostic compounds …
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy …
G Kong, M Thompson, M Collins, A Herschtal… - European journal of …, 2014 - Springer
Purpose To review the response and outcomes of 177 Lu-DOTA-octreotate
chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) …
chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) …
Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT
LM Sawicki, C Deuschl, K Beiderwellen, V Ruhlmann… - European …, 2017 - Springer
Objectives To compare the diagnostic performance of 68 Ga-DOTATOC PET/MRI and 68 Ga-
DOTATOC PET/CT in the whole-body staging of patients with neuroendocrine tumours …
DOTATOC PET/CT in the whole-body staging of patients with neuroendocrine tumours …
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
JJM Teunissen, DJ Kwekkeboom… - Endocrine-related …, 2011 - erc.bioscientifica.com
Nuclear medicine plays a pivotal role in the imaging and treatment of neuroendocrine
tumours (NETs). Somatostatin receptor scintigraphy (SRS) with [111 In-DTPA 0] octreotide …
tumours (NETs). Somatostatin receptor scintigraphy (SRS) with [111 In-DTPA 0] octreotide …